



MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients' Responses to Immunotherapies

- Presentation of AI-based screening strategy developed to identify a new generation of drug candidates, MaaT034 being the first product from the new range.
- First-time presentation of *in vitro* data for MaaT034, a new generation product, demonstrating biological activity that enhanced responses to Immune Checkpoint Inhibitors (ICIs) therapies.

Lyon, France, October 31, 2023, 6:00pm CET – [MaaT Pharma](#) (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer, announced today the details of two poster presentations at the [38th Society for Immunotherapy of Cancer \(SITC\) Annual Meeting](#), the world-leading event in immunotherapy, scheduled to be held from November 1-5, 2023, in San Diego, California, U.S.A. Presentations will include *in vitro* results for its new Artificial Intelligence (AI)-generated lead product, MaaT034, designed to improve responses to immunotherapy for patients with solid tumors. MaaT034 is the first member of the MET-C platform that can co-cultivate a healthy microbiota ecosystem. The first-in-human testing is planned for 2025, with the first clinical batches to be produced in 2024.

Nathalie Corvaia, Chief Scientific Officer, states *“we are very excited to present our first pre-clinical data at SITC showing biological activity for MaaT034, our new generation of co-cultured products and the robustness of our proprietary AI-engine, gutPrint®. MaaT034 is active in restoring the integrity of the gut barrier and stimulating immune cells leading to an improvement in the immune cell response to ICI therapy. This bolsters our confidence in our immuno-oncology approach driven by our AI engine. We are looking forward to moving to clinical evaluation in 2025.”*

Poster Presentation Details:

Poster 1 Title: [Evaluation of a new co-cultured microbiome ecosystem therapy candidate \(MaaT03X\) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in](#)

[solid tumors](#) Poster Number: 1321

Date & Location: November 3, 2023 – Exhibit Halls A & B1

Key findings for MaaT034:

- replicates, at large industrial scale, the richness and diversity of healthy native-based microbiome ecosystems
- restores the integrity of a damaged gut barrier
- activates AhR¹ pathway involved in gut homeostasis
- stimulates both myeloid and lymphoid immune cells
- improves immune cell response to ICI therapy

Poster 2 Title: [Robust Machine Learning \(ML\) approach for screening Microbiome Ecosystem Therapies \(MET\) drug candidates in combination with Immune Checkpoint Inhibitors](#)

Poster Number: 1304

Date & Location: November 3, 2023 – Exhibit Halls A & B1

Key findings for gutPrint® AI engine:

- selection and training of models to grade samples as “Responder-like” according to the baseline stool metagenomics of ICI treated cancer patients
- improvement of predictive performance compared to literature with more patient data, cross studies and indication
- application of the best performing model (mean LODO AUC = 0.65) to MaaT Pharma’s healthy donor cohort or pooled samples (mixes of stools from 4 to 8 healthy donors) classified a large majority of those as “Responder-like” microbiota (especially pooled samples)

About MaaT Pharma

MaaT Pharma, a clinical-stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single-arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

Contacts

¹ AhR: Aryl Hydrocarbon Receptor

MaaT Pharma – Investor Relations

Guillaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com

MaaT Pharma – Media Relations

Pauline RICHAUD
Senior PR & Corporate
Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com

**Trophic Communications – Corporate
Communications**

Jacob VERGHESE or Priscillia PERRIN
+49 151 7441 6179
maat@trophic.eu